Evidence map›Paper›PMID 26091453›Full record

ArticleMedicine2015

Optimal Scan Time of 18F-FDG PET in Identifying Therapeutic Efficacy Secondary to Radiofrequency Ablation of Lung Cancer: Case Report.

Wen-Qian Zhang, Yi-Li Fu, Bin Hu, Shuo Chen, Min-Fu Yang, Hui Li

Abstract readCase Reports
In one paragraph

Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wen-Qian ZhangFrom the Department of Thoracic surgery (W-QZ, Y-LF, BH, SC, HL), Beijing Institute of Respiratory Diseases, Beijing Chaoyang Hospital; and Department of Nuclear Medicine (M-FY), Chaoyang Hospital, Capital Medical University, Beijing, China.
Yi-Li Fu
Bin Hu
Shuo Chen
Min-Fu Yang
Hui Li

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography (PET)/computed tomography (CT)-guided radiofrequency ablation (RFA) has become a major treatment approach for small tumors. Identifying this quantitative dynamic 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) activity at the primary lesion can minimize misdiagnosis and allow an opportunity to reintervene. Here, we report 3 patients with nonsmall cell lung cancer (NSCLC) who underwent the ablative therapy with split-dose 18F-FDG fused PET/CT scans for early identification of residual tumors and follow-up evaluation of treatment. Our results indicate that reliable post-RFA imaging follow-up is critical in fast and efficient assessment of complete tumor resection in patients experienced the ablation procedure.

Indexed as

BronchoscopyCarcinoma, Non-Small-Cell LungCatheter AblationFemaleFluorodeoxyglucose F18HumansLung NeoplasmsMaleMiddle AgedPositron-Emission TomographyRadiopharmaceuticalsTomography, X-Ray ComputedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID26091453
PMCPMC4616549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.